Tricuspid transcatheter edge-to-edge repair (tTEER) is a catheter-based procedure that brings portions of the native tricuspid valve’s leaflets together to reduce regurgitation without replacing the valve. The STS/ACC Transcatheter Valve Therapy (TVT) Registry monitors the safety, procedural results, and follow-up outcomes of transcatheter tricuspid interventions through its tricuspid repair and replacement data collection pathway.
For patients undergoing tTEER, the registry collects clinical history, treatment indications, device information, implantation results, and adverse events. Repair-specific monitoring includes residual tricuspid regurgitation, valve gradients, single-leaflet device attachment, and complete clip detachment. Other recorded complications include bleeding, vascular injury, cardiac perforation, stroke, device embolization, and the need for another tricuspid valve intervention.
Follow-up data are collected at 30 days and one year to evaluate survival, valve function, functional status, and patient-reported health status. Echocardiography documents remaining regurgitation and valve gradients, while the KCCQ-12 helps assess symptoms, activity limitations, and quality of life. These evaluations provide a broader understanding of treatment results than successful clip placement alone.
Complete documentation and coordinated follow-up allow structural heart programs to evaluate outcomes, recognize complications, and identify opportunities for improvement. Registry-based monitoring supports ongoing assessment of patient selection and clinical care, with attention to both procedural safety and meaningful patient benefit. Its goal is to strengthen the quality and consistency of transcatheter tricuspid valve repair care.
Medicare coverage considerations: CMS covers eligible tTEER procedures under Coverage with Evidence Development (CED), requiring participation in a CMS-approved study that evaluates specified outcomes for at least 24 months. Registry reporting supports outcome assessment, but programs must also meet the applicable patient, Heart Team, and study requirements rather than relying on registry participation alone.